Anavex Life Sciences Corp. (NASDAQ: AVXL) announced that its Phase 2 clinical study of ANAVEX3-71 for schizophrenia treatment met its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE